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ABSTRACT  
Objective: The objective of this research was to formulate cinnarizine tablets using the liquid-solid compact technique to enhance its solubility and 
dissolution rate.  
Methods: Cinnarizine liquid-solid compacts were formulated using propylene glycol as the non-volatile solvent, Neusilin US2 as the carrier material, 
Aerosil 200 as the coating material and croscarmellose sodium as the disintegrant. The interaction between drug and excipients were characterized 
by Fourier-transform infrared spectroscopy (FTIR) and differential scanning calorimetry (DSC) studies. Different batches of liquid, solid compacts 
were prepared by using varying carrier-coating excipient ratio and different concentration of liquid medication. Flow parameters such as bulk 
density, tapped density, Carr’s Index, Hausner’s Ratio as well as an angle of repose were used to test the flowability of the powder blend. The liquid-
solid compacts were produced by direct compression method and were evaluated for tests such as weight variation, drug content, hardness, 
thickness, friability, wetting time, disintegration time as well as the in vitro dissolution studies.  
Results: The results of the preformulation studies of liquisolid compacts showed acceptable flow properties. The results of FTIR and DSC studies 
showed that there is no drug-excipient interactions. The different R values and concentrations were found to have a marked effect on the 
dissolution profile. Formulations with higher carrier: coating ratio (R-value) and lower drug concentrations displayed a better dissolution profile. 
The percentage of drug release of F3 with an R-value of 20 and a drug concentration of 10% was found to be 88.11% when compared to the 
conventional marketed tablet which released only 44.07% at the end of 2 h.  
Conclusion: From this research, it is inferred that liquid-solid technique is a promising and effective approach that can be used to enhance the 
dissolution rate of cinnarizine. 
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In pharmaceutical formulation and development, drug solubility is 
an important factor as it is one of the major determinants for oral 
bioavailability. The poor dissolution rate of water-insoluble drugs 
remains as a significant issue confronting the pharmaceutical 
industries. A large number of new chemical entities which have high 
potential to be developed as useful drugs have failed to reach the 
public merely due to the poor dissolution rate which results in 
unsatisfactory bioavailability. An orally administered drug must be 
insolubilized state and be able to cross the gastrointestinal tract 
(GIT) membrane to show its therapeutic effects [1]. The therapeutic 
effect of a drug relies on the bioavailability which is highly 
dependent on the solubility factor as well as the dissolution rate of 
the drug. Most of the poorly soluble drugs tend to be eliminated 
from the GIT before getting absorbed into the bloodstream [2]. 
Recently, liquid-solid technology is becoming more popular as one of 
the promising solubility enhancement technique developed by in 
improving the dissolution profile of the poorly soluble drugs [3]. By 
using this newly developed technique, it is possible to convert liquid 
medication into a dry and free-flowing powder just by using simple 
blending with the suitable carrier and coating materials [4]. A 
carrier material is basically a porous material with satisfactory 
absorption properties while the coating material usually made up of 
highly adsorptive particle which coats the wet carrier particle and 
converts the formulation into a dry powder form [5]. 
In this study, cinnarizine is used as a model drug as it is a poorly 
soluble drug which is classified under BCS Class II by having low 
aqueous solubility and high permeability. Cinnarizine belongs to 
antihistamines class of drugs, and it is known to promote cerebral 
blood flow. It is commonly prescribed for motion sickness. Due to its 
poor solubility, the therapeutic efficacy of cinnarizine is being 
limited. Hence, the objective of this research was to improve the 
solubility of cinnarizine by employing liquid-solid compact 
technique with the aim of enhancing its dissolution and subsequent 
bioavailability.  
MATERIALS AND METHODS  
Cinnarizine was a gift sample from Kotra Pharma (M) Sdn. Bhd., 
Malaysia. Polyethylene Glycol 400 and Propylene Glycol was 
purchased from Merck (Germany) while Tween 20, Tween 80, Span 
20 and Span 80, Neusilin US2 and Silica (Aerosil 200) and 
croscarmellose sodium were purchased from SIME Scientific and 
lastly, Cremophor RH 40 was purchased from BASF (Germany). 
Methods 
Solubility studies  
The solubility of cinnarizine was assessed in different non-volatile 
solvents such as Tween 20, Tween 80, Span 20, Span 80, 
polyethylene glycol-400, propylene glycol, Cremophor, and distilled 
water. 2 ml of each non-volatile solvent was taken in screw cap vials 
(5 ml) with 100 mg of drug and kept in a water bath shaker at 37 ℃ 
for 48 h. Later, each vial was centrifuged at 6000rpm for 20 min. 
Appropriate dilution of the filtered solution was done using 
methanol, and the UV absorbance was measured at 254 nm 
wavelength. The concentration of a dissolved drug is determined 
using the standard equation [6]. 
Angle of slide  
In evaluating the liquid retention potential of carrier and coating 
material angle of a slide is used as the parameter. The weighed 
amount of carrier and coating material was placed on one end of a 
shiny metal plate. Then, this end was slowly raised until the plate 
with the horizontal surface formed an angle at which the sample was 
about to slide. The experiment was done in triplicate and the 
average of the angle of the slide was calculated [7]. 
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Calculation of flowable liquid retention potential of carrier 
material (ΦCA) and coating material (ΦCO) 
Using mortar and pestle, 1g of carrier material (Neusilin US2) was 
mixed with the increasing quantity of non-volatile solvent 
(propylene glycol). For each admixture containing a constant 
amount of carrier material and a specific amount of non-volatile 
solvent, angle of slide was measured using the methods mentioned 
above. Using the following equation, the liquid retention potential of 
carrier material was calculated. Angle of slide corresponding to 33 ° 
is determined as optimal flow behavior.  
ΦCA =  
Weight of liquid solvent(mg)
Weight of carrier material(mg)
 
The above procedures were exactly repeated by using Aerosil 200 as 
the coating agent in order to calculate the flowable liquid retention 
potential of coating material and the equation used to calculate is 
shown below.  
ΦCO =  
Weight of liquid solvent(mg)
Weight of coating material(mg)
 
Calculation of R, Lf and amount of carrier and coating materials 
The loading factor (Lf
The amount of the carrier material required was calculated using the 





) was calculated using the values derived from 
liquid retention potential of carrier and coating material which 
corresponds to the angle of 33 °. The formula used to calculate the 
loading factor is shown below [8-10].  




where R = Carrier to coating material ratio 
Q = Amount of carrier material 
W =Weight of the liquid medication  
The ratio between the weight of the carrier material (Q) and weight 
of coating material (q) is represented by R. The value of R is fixed as 
5, 10 and 20. Hence, the formula used to calculate the weight of the 





Pre-compression studies  
The different formulations were evaluated for the following 
properties such as angle of repose, bulk density, tapped density, 
Hausner’s ratio, Carr’s index [11].  
Preparation of cinnarizine liquid-solid compacts  
Cinnarizine was initially dispersed in the propylene glycol with 
constant stirring using mortar and pestle until a homogeneous drug 
solution/suspension was obtained. Then the mixture of a carrier 
(Neusilin US2) and coating material (Aerosil) which were calculated 
based on the R values (5, 10 and 20) and Lf values was added to the 
above liquid medication. After complete incorporation of the liquid 
medication to the carrier and coating material, 6% w/w of 
croscarmellose sodium as the disintegrant was added to the mixture 
and mixed thoroughly. After the final liquid-solid formulation has 
been produced, the blend was compressed into tablets using rotary 
tablet press machine with 12 mm round and flat punch with a 
compression force that provides acceptable tablet hardness [12-14]. 
The final formulation of solid liquid compacts is shown in table 1. 
 


























F1 25 225 10 1.139 5 219.50 43.90 30.80 522.20 
F2 25 225 10 1.027 10 243.43 24.34 31.07 548.84 
F3 25 225 10 0.971 20 257.46 12.87 31.22 551.55 
F4 25 100 20 1.139 5 109.75 21.95 15.40 272.10 
F5 25 100 20 1.027 10 121.71 12.17 15.53 274.41 
F6 25 100 20 0.971 20 128.73 6.44 15.61 275.78 
*Each formulation 6% w/w of Croscarmellose sodium 
 
Post-compression studies  
In order to evaluate the prepared liquid-solid compacts, several 
quality control tests such as weight variation, hardness, thickness, 
friability, wetting time, drug content uniformity, disintegration, and 
dissolution test were carried out [15-17].  
In vitro dissolution studies 
Dissolution studies were performed for the all the six prepared 
formulations (F1-F6) as well as for the conventional marketed 
formulation (F7). The in vitro dissolution behaviors were assessed 
using the USP rotating paddle Electrolab Dissolution Tester (TDT-
08L). The dissolution media (0.1 N HCl) was kept at 37±0.5 °C and a 
rotation speed of 50 rpm was maintained. Once optimal conditions 
were achieved, the formulations were placed into the media. 5 ml 
aliquots were withdrawn at predetermined time intervals (10, 20, 
30, 40, 60, 80, 100 and 120 min). The withdrawn samples were 
replaced with an equal amount of fresh dissolution media to 
maintain sink conditions. The samples collected were filtered using 
a 0.45 mm Millipore nylon filter and analyzed using a UV-Vis 
spectrophotometer at a maximum wavelength of 254 nm.  
Fourier-transform infrared spectroscopy (FTIR)  
FTIR study is carried out for the identification of the pure drug as 
well as to determine the chemical interaction between the drug and 
excipients used in the formulation. 2-3 mg of samples were prepared 
and the analysis was done based on Attenuated Total Reflectance 
(ATR) method. The spectrum of a pure drug is compared with the 
spectrum of the physical mixture of drug with the excipients such as 
croscarmellose sodium, Neusilin US2, Aerosil as well as Propylene 
Glycol which were incorporated in the formulation. The spectra 
were scanned over the wave number range of 4000 to 650 cm-1
Differential scanning calorimetry (DSC) 
 [18]. 
Initially, DSC thermogram for cinnarizine was obtained to confirm 
the purity of the drug. The expected peak was in the range of 118-
122 °C [19, 20] which shows the melting point of cinnarizine. DSC 
thermograms for liquid-solid preparations was obtained as well. The 
DSC aluminum cells were used as a sample holder and blank DSC 
aluminum cell was used as the reference. Samples ranging from 2-5 
mg was weighed and used for DSC analysis. Thermograms for all the 
samples were observed over the range of 20 °C–160 °C at the 
scanning rate of 10 °C/min in a nitrogen atmosphere [21]. 
RESULTS AND DISCUSSION  
Solubility studies  
Solubility plays an integral part in this research as higher solubility 
of cinnarizine in the liquid vehicle will lead to higher dissolution rate 
since the drug will be molecularly dispersed. [22]. According to the 
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results shown in fig (1), a solubility of cinnarizine appears to be 
significantly higher in propylene glycol compared to other non-
volatile solvents. The solubility of cinnarizine in propylene glycol 
was found to be 24.8±0.8 µg/ml. Hence, propylene glycol has been 
selected as the appropriate liquid solvent to be incorporated in 
producing the solid liquid compacts. 
  
 
Fig. 1: Solubility data of cinnarizine in various non-volatile solvents, (data expressed in mean±SD (n=3), SD standard deviation) 
 
Determination loading factor (Lf
R 
) 
The flowable liquid retention potential of carrier material and coating 
material were determined from the slopes of the graphs as mentioned in 
fig (2) and fig (3). The loading factor for different R values was 
determined by incorporating these values into the following equation:  














Fig. 2: Graph determining the flowable liquid retention potential of carrier material (Neusilin US2) that corresponds to the 33 °. (Data 
expressed as a mean±SD, n =3) 
 
Pre-compression studies 
Liquid-solid formulations is based on the conversion of liquid 
formulation into a powder with good flowability and compressibility. 
Hence, testing the parameters such as bulk density, tapped density, 
Carr’s Index, Hausner’s ratio as well as an angle of repose is crucial. 
The results of the precompression studies are shown in the table (2). 
From the tests that has been done, it is clear that the R-value affects 
the flowability of the powder blend as the formulations with higher 
R-value (R=20) which are the F3 and F6 has better flow properties. 
 The concentration of the formulation also affects the flowability of 
the powder blend. It has been found better flowable and 
compressible powder system has been achieved by the least 
concentrated formulation that needs a higher amount of carrier 
material, which leads to high tablet weight. 
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Fig. 3: Graph determining the flowable liquid retention potential of coating material (Aerosil 200) that corresponds to the 33 °, (data 
expressed as a mean±SD, n =3) 
 
Table 2: Pre-compression results 
Formulation Pre-compression parameters 
Bulk density (g/cm Tapped density (g/cm3) Carr’s index (%) 3) Hausner’s ratio Angle of repose ( °) 
F1 0.252±0.001 0.317±0.002 20.505±0.154 1.258±0.036 38.40±0.363 
F2 0.277±0.002 0.346±0.001 19.942±0.343 1.249±0.006 38.29±0.395 
F3 0.299±0.004 0.372±0.003 19.623±0.432 1.244±0.007 37.92±0.582 
F4 0.285±0.002 0.346±0.001 17.630±0.340 1.214±0.005 39.03±0.137 
F5 0.291±0.002 0.354±0.001 17.796±0.797 1.216±0.012 38.20±0.375 
F6 0.295±0.004 0.353±0.002 16.431±0.093 1.196±0.001 38.40±0.605 
(Results were expressed in mean±SD, n=3) 
 
Post-compression studies 
The results of the post-compression studies are shown in table (3). 
Based on the results obtained, all the formulations passed the weight 
variation, drug content uniformity, and disintegration test as the 
results lie within the acceptable range based on the British 
Pharmacopeia limits. Tablets (F1, F2, and F3) with a lower 
concentration (10%) which corresponds to the higher tablet weight 
has larger hardness compared to the tablets (F4, F5, F6) having a 
higher concentration (20%). F1, F2 and F3 passed the friability test 
as they lie within the approved range of less than 1%. The friability 
of F4, F5, and F6 was slightly above the range hence they have poor 
mechanical strength. All the formulations were disintegrated within 
3 min. wetting time is based on the tablet’s inner structure as well as 
the hydrophilicity of the excipients. The wetting time for all the 
formulations was fast which may be due to the high water 
absorption capacity of the croscarmellose sodium which is highly 
hydrophilic in nature. 
 















F1 526.53±2.24 2.83±0.26 0.95±0.11 5.14±0.001 97.58±3.02 2.34±0.089 62.33±2.52 
F2 545.49±2.55 3.08±0.2 0.93±0.04 5.20±0.001 95.23±7.14 2.89±0.185 63.33±2.52 
F3 547.28±2.50 3.42±0.4 0.73±0.04 5.18±0.002 98.92±4.45 2.61±0.460 52.00±2.00 
F4 270.94±1.49 2.58±0.2 1.14±0.07 2.07±0.002 95.1±6.2 1.28±0.332 32.33±1.53 
F5 272.91±2.62 2.75±0.27 1.4±0.09 2.22±0.003 96.11±4.7 2.03±0.176 37.00±1.00 
F6 275.34±2.04 2.41±0.49 1.17±0.15 2.30±0.003 95.67±6.5 1.74±0.618 31.66±2.08 
F7 306.35±2.92 2.25±0.27 3.71±0.92 2.34±0.003 95.88±5.82 1.71±0.404 47.33±2.08 
(Results were expressed in mean±SD, n=3) 
 
FTIR studies  
The results obtained confirms the purity of cinnarizine since the 
peak values obtained were similar as the characteristic peak 
values. Fig. (4) Show the results of the FTIR analysis of pure drug 
as well as the drug mixed with each excipient separately at the 
fixed ratio. From the results, it is evident that there is no drug 
excipient incompatibilities between the drug (cinnarizine) and 
the excipients (Neusilin US2, Aerosil 200, propylene glycol and 
croscarmellose sodium) when the drug is analyzed with each 
excipient separately.  
To justify this results, FTIR analysis was also carried out on the liquid-
solid compact (after direct compression), and comparison was done 
with the spectra of pure cinnarizine as shown in fig. (5). The appearance 
of all the characteristic peak and absence of any new peaks in the IR 
spectra of liquid-solid compact, F3 shows the absence of any chemical 
interaction between the cinnarizine and the excipients [23]. 
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Fig. 4: Split view of IR Spectra of pure drug and mixture of pure drug and excipients in equal ratio 
 
 
Fig. 5: Comparison of IR spectra between the pure drug and the formulated liquid-solid compact (F3) 
 
 
Fig. 6: DSC thermogram of cinnarizine (pure drug) 
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Fig. 7: DSC thermogram of liquid-solid compact (F3) 
 
DSC studies  
DSC of pure cinnarizine showed a characteristic, sharp endothermic 
peak at 123.88 °C which is associated with the melting point of the drug 
and indicates the crystalline nature of cinnarizine as shown in fig. 6.  
From the fig. 7 we can see that the thermogram of F3 shows a 
complete loss of cinnarizine peak indicating a change to the 
amorphous state of the drug. The results obtained justifies that the 
cinnarizine in the solid liquid formulations has lost its crystalline 
structure and the drug is present in its molecularly dispersed state. 
Thus, we can conclude that cinnarizine has been completely 
solubilized in Propylene Glycol [24]. 
In vitro dissolution studies 
All the seven formulations were subjected for in vitro dissolution to 
study the drug release profile using the dissolution apparatus. From 
fig. (8), it was observed that liquid-solid compact formulations (F1-
F6) exhibited enhanced dissolution profile when compared to the 
marketed formulation (F7). This is evident because the formulations 
with the drug dissolved in the propylene glycol causes the drug to be 
molecularly dispersed resulting in increased surface area for wetting 
and subsequent dissolution [25, 26]. The percentage of drug release 
of F3 was found to be the highest with a value of 88.11%, and the 
lowest percentage of drug release was from the F7 which represents 
the conventional marketed tablet with a cumulative percentage 
value of 44.07% at 120 min (fig. 9).  
The concentration of the drug in the liquid medication also plays an 
integral part in the drug release profile. When the dissolution profiles of 
F3 (10%) and F6 (20%) are compared, there is a significant difference 
observed. The dissolution rate of the solid liquid compacts increases 
with the decrease in concentration of the drug in the liquid medication. 
This is because in a highly concentrated formulation, the amount of drug 
is available in the molecularly dispersed state is lower compared to the 
less concentrated formulation [27, 28]. 
Besides, the role of R-value which resembles the powder excipient ratio 
also influences the in vitro drug release profile. Comparisons have been 
done between the formulations with the same concentrations but 
different R-value. F3 which has a higher R-value of 20 shown to be 
having a better dissolution rate of 88.11% at 120 min compared to F1 
which released 74.18% due to the lower R-value of just 5. Generally, the 
solid liquid compacts with high R-value comprised of the relatively large 
amount of powder admixture (carrier and coating materials) and the 
amount of non-volatile solvent available per powder substrate is 
relatively larger. Hence the solid liquid compacts with high R values 
showed a better dissolution profile [29, 30]. 
 
 
Fig. 8: Dissolution profile of F1-F7 in 0.1N HCl (data expressed as a mean±SD, n =3) 
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Fig. 9: Comparison of dissolution profile of F3 (Optimized liquid-solid compact) an F7 (conventional tablet), (data expressed as a 
mean±SD, n =3) 
 
CONCLUSION 
The solid liquid compacts were successfully formulated using the 
appropriate amount of non-volatile solvent, carrier and coating 
material as well as the disintegrant which were calculated based on 
the loading factor and the liquid retention potential of carrier and 
coating material. The results of the various evaluation tests show 
that the solid liquid compacts produced were within acceptable 
limits. The dissolution rate results show that the main objective of 
this research has been met because there is a marked improvement 
in the dissolution profile of the F3 which higher carrier to coating 
ratio and lower drug concentrations when compared to that of the 
conventional tablet. Hence, it is concluded that liquid-solid compact 
technique is a novel approach that can be employed to increase the 
solubility and dissolution rate of cinnarizine. 
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